
Darolutamide Improves Quality of Life in Metastatic Prostate Cancer
Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) demonstrated positive impacts on health-related quality of life (HRQoL) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), including clinically meaningful delays in pain …